IQ-AI Limited (GB:IQAI) has released an update.
Imaging Biometrics, a subsidiary of IQ-AI Limited, has announced that the U.S. FDA has awarded their lead drug candidate, IB-003, with a Rare Pediatric Disease Designation for treating the aggressive brain tumor, ATRT. This significant development could expedite the drug’s review process and, if approved, allow the company to receive a priority review voucher. The designation highlights the urgent need for new treatments for children with ATRT, as current options are limited and outcomes remain poor.
For further insights into GB:IQAI stock, check out TipRanks’ Stock Analysis page.
